Operating Companies in China
Johnson & Johnson is the world’s most comprehensive and broadly-based healthcare company. Guided by the values of its Credo, Johnson & Johnson is dedicated to the aspiration of “caring for the world, one person at a time.”
Since the founding of its first joint venture in China in 1985, Johnson & Johnson has been an industry leader in the healthcare market. Through the company’s advanced healthcare solutions, Johnson & Johnson helps to bring a positive impact to the health and life quality of Chinese families. Today, Johnson & Johnson’s businesses span three sectors in China: consumer and personal care; pharmaceuticals and medical devices. The company currently employs approximately 10,000 people across more than 90 locations, including Beijing, Shanghai, Guangzhou, Suzhou and Xi’an. In 2013, the company announced plans to build a large state-of-the-art manufacturing facility in Xi’an to serve China and the broader Pan-Asia region.
Johnson & Johnson is the first multinational in China to achieve the “end-to-end” R&D model, which nurtures the development of early-discoveries into clinical applications. The achievement exemplifies Johnson & Johnson’s commitment to promoting innovation as a driving force of China’s economic growth. Today, Johnson & Johnson has established three R&D organizations in China, and an Asia Pacific Innovation Center (APIC) recently opened in Shanghai to connect innovations from China and the region to the global market.
Collaborating closely with start-up companies and research institutions and talent, APIC will assist organizations in nurturing early-discoveries through the various stages of development by bringing in the required funding and expertise to turn discoveries into clinical applications. APIC will also play a key role in sourcing external innovation to support product pipelines across Johnson & Johnson, addressing the greatest unmet needs of patients and consumers in China, and in emerging global markets.
As a responsible corporate citizen, Johnson & Johnson actively participates in major events. The company was honored with the privilege of being an official worldwide partner of the 2008 Beijing Olympic and Paralympics Games, and the global sponsor of US Pavilion at the 2010 Shanghai Expo.
Johnson & Johnson has initiated an accelerated China growth strategy, connecting its global resources to further unify its core business capabilities in the China market. This strategy will further accelerate Johnson & Johnson’s pace in creating value through innovation, achieving excellence in execution and leading with purpose, as well as enabling the company to realize its commitment of contributing significant health benefits to the Chinese society.
Johnson & Johnson was ranked No. 5 in Barron’s annual list of the world’s most respected companies in 2014, recognizing the company’s contributions to advancing the health and well-being of people across the globe.
In 2015, J&J joined the U.S. Fortune magazine list of the World’s Most Admired Companies for the 31st consecutive year. Most notable was our ascension to number 11 on the list, from 19 last year. Within the pharmaceutical industry, we ranked first, continuing our leadership from 2014.
Johnson & Johnson's Consumer segment includes products for baby care, body care, facial skin care, sun care, and feminine personal care, allergy care, wound care, cough and cold care, digestive health, oral care, and pain care.
The Medical Devices segment produces a broad range of innovative products used primarily by healthcare professionals in the fields of orthopaedics (e.g. joint reconstruction, trauma, spine, sports medicine, carnio maxillofacial, and power tools), minimally invasive and open surgery (e.g. wound closure, surgical staplers, ultrasonic devices, synthetic mesh devices and absorbable hemostats), electrophysiology (e.g. catheter based technology), cardiology and endovascular (e.g. access products for interventional cardiology), diabetes care ( e.g. blood glucose monitors), aesthetics (e.g. breast implants),infection prevention (e.g. sterilization system) and vision care.
The Pharmaceutical segment’s broad portfolio targets unmet medical needs across several therapeutic areas, including oncology (e.g., multiple myeloma and prostate cancer), immunology (e.g., rheumatoid arthritis, irritable bowel disease and psoriasis), neuroscience (e.g., schizophrenia, dementia and pain), infectious disease (e.g., HIV/AIDS, Hepatitis C and tuberculosis), and cardiovascular and metabolic diseases (e.g., diabetes).